Single Blinded First CMC Osteoarthritis Treatment
Randomized Single Blinded First CMC Osteoarthritis Treatment: Therapy and Bracing Alone vs. Intra-Articular Corticosteroid Injection vs Intra-Articular Leukocyte Depleted Platelet Rich Plasma
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Naem Mufarreh
- Phone Number: 937-298-4331
- Email: naem.mufarreh@ketteringhealth.org
Study Locations
-
-
Ohio
-
Centerville, Ohio, United States, 45459
- Orthopedic Associates of Southwest Ohio
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Stage 1-3 osteoarthritis of the basal joint
Exclusion Criteria:
- Patients with Stage 4 1st carpometacarpal joint arthritis as described by Eaton
- Patients who have received a corticosteroid injection in the last year to the 1st CMC joint on the proposed study side
- Patients who have scaphotriquetral, radioscaphoid, or scaphotrapezial osteoarthritis
- Patients who have concurrent DeQuervain's tenosynovitis or intersection syndrome or have been treated for either of these in the last 3 months
- Patients undergoing evaluation of cervical radiculopathy
- Patients with fibromyalgia or inflammatory rheumatic disease
- Patients with Pressier disease, Kienbock's, or avascular necrosis of the scaphoid
- Patients with any history of primary or secondary bone tumor
- Patients that are pregnant or terminally ill
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: PRP
Intra-articular injection of platelet rich plasma.
|
Platelet Rich plasma
|
|
Active Comparator: Corticosteroid
Intra-articular injection of kenalog.
|
Kenalog
|
|
Placebo Comparator: Normal Saline
Intra-articular injection of normal saline
|
Control Group - Placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Disabilities arm shoulder and hand score
Time Frame: 1 year
|
functional score
|
1 year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pinch Strength
Time Frame: 1 year
|
Objective measurement
|
1 year
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Visual Analog Score
Time Frame: 1 year
|
Pain reduction
|
1 year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 17-008
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Osteoarthritis Thumb
-
NCT07458971Not yet recruitingThumb Osteoarthritis | Trapeziometacarpal Osteoarthritis | Carpometacarpal Osteoarthritis | Thumb Basal Joint Osteoarthritis
-
NCT07405983RecruitingOsteoarthritis Thumb | Thumb Carpometacarpal Joint Osteoarthritis
-
NCT07569549Not yet recruitingThumb Osteoarthritis | Thumb Carpometacarpal Joint Osteoarthritis | Basal Thumb Osteoartrithis | Carpometacarpal (CMC) Joint Arthritis
-
NCT07491302Not yet recruiting
-
NCT07552831Not yet recruiting
-
NCT04627259Active, not recruitingThumb Osteoarthritis | Thumb Injury | Thumb Fracture | Thumb Laceration
-
NCT07614269Not yet recruiting
-
NCT06171529Enrolling by invitationOsteoarthritis | Osteoarthritis Thumb Base Joint | Carpometacarpal Osteoarthritis | Thumb
-
NCT05247398CompletedThumb Carpometacarpal Osteoarthritis | Thumb Basal Joint Osteoarthritis
-
NCT07148349Active, not recruiting
Clinical Trials on Platelet Concentrate
-
NCT02081170UnknownMacular Hole With High Myopia (Spherical Equivalent ≤ -6.0 Diopters) or, | Large Size Macular Hole (Diameter > 600 Microns) or | Recurred or Failed Macular Hole From Previous Surgery | or Chronic Macular Hole (Symptom Duration > 6 Months)
-
NCT02885038CompletedLymphoma | Multiple Myeloma | Hodgkin Disease | Lymphocytic Leukemia
-
NCT02468492Completed
-
NCT05820126Recruiting
-
NCT04807621RecruitingCongenital Heart Disease
-
NCT03492515UnknownImmune Thrombocytopenia
-
NCT00295126TerminatedTooth Loss | Jaw, Edentulous | Maxillary Diseases
-
NCT05191732CompletedAnterior Cruciate Ligament Reconstruction
-
NCT00514241Completed